Free Trial
OTCMKTS:BPMUF

Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

Basilea Pharmaceutica logo
$52.83 0.00 (0.00%)
(As of 12/17/2024 ET)

About Basilea Pharmaceutica Stock (OTCMKTS:BPMUF)

Key Stats

Today's Range
$52.83
$52.83
50-Day Range
$51.26
$52.83
52-Week Range
$38.60
$52.83
Volume
N/A
Average Volume
117 shs
Market Capitalization
$626.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections. In addition, the company provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as offers treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. Further, it offers Fosmanogepix, an antifungal drug for the treatment of Candidemia which in Phase II clinical trials. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.

Receive BPMUF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Basilea Pharmaceutica and its competitors with MarketBeat's FREE daily newsletter.

BPMUF Stock News Headlines

Kepler Capital Keeps Their Buy Rating on Basilea Pharmaceutica (BSLN)
Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Short Interest Update
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Innoviva enters distribution, license agreement with Basilea for Zevtera
Basilea Pharmaceutica AG (BSLN.SW)
Basilea Pharmaceutica (BSLN) Gets a Buy from Kepler Capital
See More Headlines

BPMUF Stock Analysis - Frequently Asked Questions

Basilea Pharmaceutica's stock was trading at $41.00 at the beginning of 2024. Since then, BPMUF stock has increased by 28.9% and is now trading at $52.83.
View the best growth stocks for 2024 here
.

Basilea Pharmaceutica subsidiaries include these companies: Conec UK Limited.

Shares of BPMUF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
12/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:BPMUF
CIK
N/A
Employees
147
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$175.50 million
Cash Flow
$1.13 per share
Book Value
($0.94) per share

Miscellaneous

Free Float
N/A
Market Cap
$626.04 million
Optionable
Not Optionable
Beta
0.78

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (OTCMKTS:BPMUF) was last updated on 12/18/2024 by MarketBeat.com Staff
From Our Partners